197 related articles for article (PubMed ID: 12134020)
1. Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment.
Abdelhamed AM; Kelley CM; Miller TG; Furman PA; Isom HC
J Virol; 2002 Aug; 76(16):8148-60. PubMed ID: 12134020
[TBL] [Abstract][Full Text] [Related]
2. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.
Delaney WE; Miller TG; Isom HC
Antimicrob Agents Chemother; 1999 Aug; 43(8):2017-26. PubMed ID: 10428929
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus.
Delaney WE; Isom HC
Hepatology; 1998 Oct; 28(4):1134-46. PubMed ID: 9755254
[TBL] [Abstract][Full Text] [Related]
4. Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay.
Abdelhamed AM; Kelley CM; Miller TG; Furman PA; Cable EE; Isom HC
Antimicrob Agents Chemother; 2003 Jan; 47(1):324-36. PubMed ID: 12499209
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma.
Parvez MK; Sehgal D; Sarin SK; Basir SF; Jameel S
World J Gastroenterol; 2006 May; 12(19):3006-14. PubMed ID: 16718779
[TBL] [Abstract][Full Text] [Related]
6. In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication.
Heipertz RA; Miller TG; Kelley CM; Delaney WE; Locarnini SA; Isom HC
J Virol; 2007 Apr; 81(7):3068-76. PubMed ID: 17215289
[TBL] [Abstract][Full Text] [Related]
7. Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector.
Lucifora J; Durantel D; Belloni L; Barraud L; Villet S; Vincent IE; Margeridon-Thermet S; Hantz O; Kay A; Levrero M; Zoulim F
J Gen Virol; 2008 Aug; 89(Pt 8):1819-1828. PubMed ID: 18632952
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro.
Vincent IE; Lucifora J; Durantel D; Hantz O; Chemin I; Zoulim F; Trepo C
Antivir Ther; 2009; 14(1):131-5. PubMed ID: 19320247
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients.
Moses SE; Lim Z; Zuckerman MA
Expert Rev Anti Infect Ther; 2011 Oct; 9(10):891-9. PubMed ID: 21973301
[TBL] [Abstract][Full Text] [Related]
10. Involvement of Host ATR-CHK1 Pathway in Hepatitis B Virus Covalently Closed Circular DNA Formation.
Luo J; Luckenbaugh L; Hu H; Yan Z; Gao L; Hu J
mBio; 2020 Feb; 11(1):. PubMed ID: 32071277
[TBL] [Abstract][Full Text] [Related]
11. Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells.
König A; Yang J; Jo E; Park KHP; Kim H; Than TT; Song X; Qi X; Dai X; Park S; Shum D; Ryu WS; Kim JH; Yoon SK; Park JY; Ahn SH; Han KH; Gerlich WH; Windisch MP
J Hepatol; 2019 Aug; 71(2):289-300. PubMed ID: 31077792
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus (HBV)-specific short hairpin RNA is capable of reducing the formation of HBV covalently closed circular (CCC) DNA but has no effect on established CCC DNA in vitro.
Starkey JL; Chiari EF; Isom HC
J Gen Virol; 2009 Jan; 90(Pt 1):115-26. PubMed ID: 19088280
[TBL] [Abstract][Full Text] [Related]
13. Establishment of Cre-mediated HBV recombinant cccDNA (rcccDNA) cell line for cccDNA biology and antiviral screening assays.
Wu M; Li J; Yue L; Bai L; Li Y; Chen J; Zhang X; Yuan Z
Antiviral Res; 2018 Apr; 152():45-52. PubMed ID: 29432776
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
15. β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity.
Hu Y; Cheng X; Cao F; Huang A; Tavis JE
Antiviral Res; 2013 Sep; 99(3):221-9. PubMed ID: 23796982
[TBL] [Abstract][Full Text] [Related]
16. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
Lai CL; Wong D; Ip P; Kopaniszen M; Seto WK; Fung J; Huang FY; Lee B; Cullaro G; Chong CK; Wu R; Cheng C; Yuen J; Ngai V; Yuen MF
J Hepatol; 2017 Feb; 66(2):275-281. PubMed ID: 27639844
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of novel strategies to combat hepatitis B virus targetting wild-type and drug-resistant mutants in experimental models.
Zoulim F
Antivir Chem Chemother; 2001; 12 Suppl 1():131-42. PubMed ID: 11594680
[TBL] [Abstract][Full Text] [Related]
18. Betaine Inhibits Hepatitis B Virus with an Advantage of Decreasing Resistance to Lamivudine and Interferon α.
Zhang M; Wu X; Lai F; Zhang X; Wu H; Min T
J Agric Food Chem; 2016 May; 64(20):4068-77. PubMed ID: 27144395
[TBL] [Abstract][Full Text] [Related]
19. Combination of small interfering RNA and lamivudine on inhibition of human B virus replication in HepG2.2.15 cells.
Li GQ; Xu WZ; Wang JX; Deng WW; Li D; Gu HX
World J Gastroenterol; 2007 Apr; 13(16):2324-7. PubMed ID: 17511031
[TBL] [Abstract][Full Text] [Related]
20. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
